Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Adds To Hemophilia A Problems

 
• By Andrew McConaghie
Sangamo
Sanofi's decision means Sangamo has just pharma partner left - Pfizer - among its clinical trial programs. • Source: Alamy

More from Business

More from Scrip